Skip to content

LSD: all studies

Page 196 of 282: studies 1,951 to 1,960 of 2,815, newest first. Back to the LSD overview

Research

Efficacy and Safety of Four Psychedelic-Assisted Therapies for Adults with Symptoms of Depression, Anxiety, and Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis

Journal of Psychoactive Drugs November 15, 2023 Anees Bahji, Isis Lunsky, Gilmar Gutierrez et al. 21 citations

There has been a resurgence in psychedelic research for managing psychiatric conditions in recent years. This study aimed to present a comprehensive review of the current state of the field by applying a systematic search strategy for articles on the effectiveness and tolerability of four psychedelic-assisted therapies (psilocybin, lysergic acid diethylamide [LSD],...

DOI: 10.1080/02791072.2023.2278586 (opens in new tab) Full text (opens in new tab) PTSD Psychedelic-assisted therapies Anxiety disorders Mental health treatment +3

The entropic heart: Tracking the psychedelic state via heart rate dynamics

bioRxiv (Cold Spring Harbor Laboratory) November 9, 2023 Fernando E. Rosas, Pedro A. M. Mediano, Christopher Timmermann et al. 14 citations preprint

A growing body of work shows that autonomic signals provide a privileged evidence-stream to capture various aspects of subjective and neural states. This work investigates the potential for autonomic markers to track the effects of psychedelics — potent psychoactive drugs with important scientific and clinical value. For this purpose, we introduce a novel Bayesian framework to estimate the...

DOI: 10.1101/2023.11.07.566008 (opens in new tab) Full text (opens in new tab) Psilocybin Heart rate variability Artificial intelligence Hallucinogen +1

Managing expectations with psychedelic microdosing

npj Mental Health Research November 8, 2023 Omer A. Syed, Benjamin Tsang 4 citations

The recent years have seen an unprecedented surge of psychedelic research. Studies with psilocybin (colloquially known as magic mushrooms), in particular, have shown promise in ameliorating symptoms of treatment-refractory depression, anxiety, and substance use disorder, among others 1 , 2 . Microdosing, the practice of regularly taking roughly a tenth of full psychedelic doses, is becoming...

DOI: 10.1038/s44184-023-00044-9 (opens in new tab) Full text (opens in new tab) Recreational use Mental health Applied psychology Psychotherapist

Beyond the 5-HT2A Receptor: Classic and Nonclassic Targets in Psychedelic Drug Action.

Journal of Neuroscience November 8, 2023 Lindsay P. Cameron, Joseph Benetatos, Vern Lewis et al. 88 citations

Serotonergic psychedelics, such as psilocybin and LSD, have garnered significant attention in recent years for their potential therapeutic effects and unique mechanisms of action. These compounds exert their primary effects through activating serotonin 5-HT2A receptors, found predominantly in cortical regions. By interacting with these receptors, serotonergic psychedelics induce alterations in...

DOI: 10.1523/jneurosci.1384-23.2023 (opens in new tab) Full text (opens in new tab) Psychedelics Brain chemistry Mental health Pharmacology

Towards a New Materialism in Psychedelic Studies

Deleuze and Guattari Studies November 1, 2023 Daan F. Oostveen

We are currently living through a period of ‘psychedelic renaissance’, with an increased interest, both in clinical research and in society at large, in the use of psychedelic substances such as LSD, psylocybin, DMT and mescaline. This interest, however, has recently led to an increased influx of venture capital and a fast emerging psychedelic start-up ecosystem. In this article, I will discuss...

Psychedelic Drugs or Hallucinogens: Exploring Their Medicinal Potential.

Cureus November 1, 2023 Priyanshu Raj, Shyambabu Rauniyar, Bhagyesh Sapkale 8 citations

Serotonergic hallucinogens also referred to as psychedelics, are psychoactive substances that profoundly alter perception, mood, and cognitive processes. These substances, historically intertwined with religious and cultural rituals, offer profound effects that extend beyond mere hallucinations to profoundly altered states of consciousness. Notable compounds like Lysergic acid diethylamide...

DOI: 10.7759/cureus.48719 (opens in new tab) Full text (opens in new tab) Hallucinogens uses Psychedelic drug research Psychedelic drugs Psychedelic medicines +4

What Is Psychedelic Experience?

Psychedelic Experience October 26, 2023 Aidan Lyon

Abstract This chapter introduces the book's central question: what is a psychedelic experience? Upon reviewing the exchanges between Aldous Huxley and Humphry Osmond concerning their introduction of the term 'psychedelic', the chapter proposes that we should understand the notion along the lines they intended. Their idea was that substances such as psilocybin and LSD induce experiences that...

Chronic psychosis associated with new hallucinogenic drug 25I-NBOMe

European Psychiatry October 23, 2023 O. Martin-Santiago, G. Guerra-Valera, C. Alario-Ruiz et al.

Introduction The presence of perceptual disturbances and psychotic symptoms associated with substance abuse are widely known. While the abuse of substances is becoming more widespread, there is a general perception that their use entails fewer risks. 25I-NBOMe is a recently introduced hallucinogenic drug producing visual hallucinations and euphoria. Although people consume it like LSD, its...

The suitability of zebrafish (danio rerio) as an optimal organism to further investigate the associated schizophrenia-like phenotype

European Psychiatry October 23, 2023 I. B. Nita, O. D. Ilie, A. S. Ciobica et al.

Introduction Zebrafish (Danio rerio) has evolved over the years as a preferred organism due to its vast repertoire in research fields that mimic a targeted phenotype, particularly behavioral typologies and specific attributes comparable to murine models and relatively high homology with humans. Considering this consideration, different pharmacological treatments have been tested and proven that...

Cellular rules underlying psychedelic control of prefrontal pyramidal neurons

bioRxiv (Cold Spring Harbor Laboratory) October 23, 2023 Tyler G. Ekins, Isla A. W. Brooks, Sameer Kailasa et al. 17 citations preprint

ABSTRACT Classical psychedelic drugs are thought to increase excitability of pyramidal cells in prefrontal cortex via activation of serotonin 2 A receptors (5-HT2 A Rs). Here, we instead find that multiple classes of psychedelics dose-dependently suppress intrinsic excitability of pyramidal neurons, and that extracellular delivery of psychedelics decreases excitability significantly more than...

DOI: 10.1101/2023.10.20.563334 (opens in new tab) Full text (opens in new tab) Serotonin Prefrontal cortex Consumer neuroscience Pyramidal cell +2